Sunitinib Malate

Licensed by Pfizer Catalog No.S1042

Sunitinib Malate Chemical Structure

Molecular Weight(MW): 532.56

Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 97 In stock
USD 147 In stock
USD 447 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 41 Publications

11 Customer Reviews

  • PDGF-AA induces Ezh2 expression and proliferation in juvenile islets but not in adult islets. Western immunoblots of indicated islet proteins from 3 week or 9 month-old WT islets 2 days after exposure to PDGF-AA alone, or PDGF-AA plus RTK inhibitors Sunitinib.

    Nature 2011 478(7369):349-55. Sunitinib Malate purchased from Selleck.

    Assessment of effects on human juvenile or adult islets after exposure to PDGF-AA (50 ng/ml) for 2 days, with or without Sunitinib (2 uM) or U0126 (10 uM)co-treatment. Average percentage of BrdU+ insulin+ cells was morphometry from sectioned islets immunostained for insulin (green), glucagon (white) and BrdU (red). n = 3-6 independent experiments.

    Nature 2011 478(7369):349-55. Sunitinib Malate purchased from Selleck.

  • Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Sunitinib Malate purchased from Selleck.

    Sunitinib decreases FLT-3 and RET phosphor ylation but increases ERK phosphorylation in a time-dependent manner. H295R and SW13 cells were treated with sunitinib (10 nM) for various time points as indi-cated. Cell lysates were prepared and phospho-FLT-3, RET, and ERK levels were monitored by Western Blot-ting. Re-probing against FLT-3, RET, and ERK was done to ensure equal protein loading.

    Surgery 2012 152, 1045-50. Sunitinib Malate purchased from Selleck.

  • Sunitinib or PD98059 decreases cell proliferation in a dose-dependent manner. H295R and SW13 cells were treated with various concentration of sunitinib or PD98059 for 48 hours as indicated. Treated cells were subjected to the MTS proliferation assay. Similar experiments were repeated 3 times. Histograms represent relative % of OD490 nm absorbance (* P < .05). All data are relative multiples of expression compared with untreated cells. The data are representative of three experiments and are expressed as the mean ?SE.

    Surgery 2012 152, 1045-50. Sunitinib Malate purchased from Selleck.

    Autophagic activation in sunitinib- and sorafenib- but not AZD6244-treated cells. Medullary thyroid cancer-1.1 (MTC-1.1; A) and TT ( B) cells were treated with dimethyl sulfoxide (DMSO), sunitinib (50 nM), sorafenib (10 nM), AZD6244 (30 nM), or everolimus (20 nM) for 48 hours. Cell lysates were prepared, and light chain 3 (LC3)-I and -II cleaved caspase-3 protein levels were monitored by Western blotting. Reprobing against actin was per formed to ensure equal protein loading. ( C ) MTC-1.1 and TT cells were transiently transfected with autophagy protein 5 (Atg-5) small inter fering RNA. Transfection with scrambled small inter fering RNA was used as a control. After transfection, cells with and without Atg-5 knockdown were exposed to DMSO or 20 nM of everolimus for 48 hours. Cell lysates were pre- pared and LC3-I and -II protein expression levels were monitored by Western blotting. Reprobing against Atg-5 was per formed to monitor Atg-5 knockdown efficiency. Reprobing against actin was per formed to ensure equal protein.

    Surgery 2012 152, 1142-9. Sunitinib Malate purchased from Selleck.

  • Autophagy inhibition blocks the antiproliferative effects of sunitinib and sorafenib but not AZD6244. Medullary thyroid cancer–1.1 (MTC-1.1) and TT cells were transfected transiently with scrambled or autophagy protein 5 (Atg-5) small inter fering RNA. After transfection, cells with and without Atg-5 knockdown were exposed to sunitinib (50 nM), sorafenib (10 nM), and AZD6244 (30 nM) for 48 hours. Treated cells were subjected to a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium proliferation assay. Similar experiments were repeated 3 times. Histograms represent the relative percent of OD490 nM absorbance. The asterisk indicates significance versus scrambled small inter fering RNA–treated control ( P < .05). All data are relative multiples of expression compared to untreated cells. The data are representative of 3 experiments and are expressed as the mean ± the standard error.

    Surgery 2012 152, 1142-9. Sunitinib Malate purchased from Selleck.

    Sunitinib limits the colonial growth of HT-29 by downregulating HIF-1a. (A) The number and size of colonies formed in soft agar. The numbers of small colonies (<50 μm diameter) were not different among conditions of a serial concentration of sunitinib. On the contrary, large colonies (>50 μm diameter) disappeared after incubation with sunitinib. Each point represents the mean and SD from four separate experiments. (B) HIF-1a expression and hypoxia within HT-29 colony. After colonies grew for 4 weeks, HIF-1a and hypoxia were visualized by immunofluoroscence staining. Bar = 20 μm.

    Biochem Bioph Res Co 2010 398, 205–211. Sunitinib Malate purchased from Selleck.

  • 2. Sunitinib downregulates HIF-1a. (A) Dose-dependent repression of HIF-1a protein level by sunitinib in HT-29. HT-29 cells were incubated under normoxic (N) or hypoxic (H) conditions in the presence of sunitinib for 24 h. HIF-1a and ARNT proteins in total cell lysates were analyzed by Western blotting. (B) Sunitinib attenuates the hypoxic induction of HIF-1 target genes. RNAs were isolated from HT-29 cells subjected to normoxia (N) or hypoxia (H) in the presence of sunitinib for 16 h. The mRNAs of HIF-1a and its target genes were analyzed by RT-PCR and autoradiography. PGK1 indicates phosphoglycerate kinase 1; PDK1, pyruvate dyhydrogenase kinase 1; CAIX, carbonic anhydrase IX. (C) Sunitinib-induced HIF-1 inhibition. Epo-enhancer and b- galactosidase reporter plasmids were co-transfected into HEK293 cells. After 16 h incubation, luciferase and b-galactosidase activities were measured. *P < .05 versus the hypoxic control.

     

     

    Biochem Bioph Res Co 2010 398, 205–211. Sunitinib Malate purchased from Selleck.

    Sunitinib inhibits 50-UTR-dependent translation of HIF-1a. (A) 50 cap-dependent translational activity of HIF-1a. The luciferase reporter plasmid contains the HIF-1a 50-UTR segment between the tk promoter and the luciferase gene. HT-29 cells were co-transfected with the reporter plasmid (8 lg per 100-mm dish) and the b-gal plasmid (4 μg). After 16 h incubation under normoxic or hypoxic conditions with sunitinib, cells were lysed and subjected to luciferase assay. *P < .05 versus the hypoxic control. (B) IRES-dependent translational activity of HIF-1a. The luciferase reporter plasmid contains the HIF-1a 50-UTR segment between the GFP gene and the luciferase gene. HT-29 cells were co-transfected with the reporter plasmid (8 μg) and the b-gal plasmid (4 μg). *P < .05 versus the hypoxic control. (C) Sunitinib inhibits phosphorylation of Akt. After 8 h incubation under hypoxic condition with sunitinib, HT-29 cells were lysed and subjected to Western blotting. (D) Sunitinib suppresses HIF-1a in VHL-null RCC4 cells. VHL (-/-) RCC4 cells were incubated under normoxic conditions sunitinib for 8 h, and HIF-1a in total cell lysates was analyzed by Western blotting.

     

     

    Biochem Bioph Res Co 2010 398, 205–211. Sunitinib Malate purchased from Selleck.

  • Experimental layout for VEGF signaling blocking and LCMV infection in WT mice. Mice received two injections on day 0 and 3 p.i. of Abs as described in Material and Methods, or daily gavage of the VEGFR/PDGFR-inhibitor sunitinib. Inguinal LN volume on day 0 (D0) or day 8 (D8) p.i. after treatment of mice with control Ig or anti-VEGFR2, anti-VEGF-A Abs or sunitinib. Pooled from 1-2 independent experiments with 3-5 mice per treatment. D. Total HEV length on day 0 (D0) or day 8 (D8) p.i. as in C. No significant difference was found in C and D between day 8 control Ig and Ab- or inhibitor-treated values (One-way ANOVA).

    AACR Sunitinib Malate purchased from Selleck.

Purity & Quality Control

Choose Selective PDGFR Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.
Targets
Kit [1]
(Cell-free assay)
FLT3 [1]
(Cell-free assay)
PDGFRβ [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
FGFR1 [1]
(Cell-free assay)
2 nM 80 nM 2.9 μM
In vitro

Sunitinib also potently inhibits Kit and FLT-3. [1] Sunitinib is a potent ATP-competitive inhibitor of VEGFR2 (Flk1) and PDGFRβ with Ki of 9 nM and 8 nM, respectively, displaying >10-fold higher selectivity for VEGFR2 and PDGFR than FGFR-1, EGFR, Cdk2, Met, IGFR-1, Abl, and src. In serum-starved NIH-3T3 cells expressing VEGFR2 or PDGFRβ, Sunitinib inhibits VEGF-dependent VEGFR2 phosphorylation and PDGF-dependent PDGFRβ phosphorylation with IC50 of 10 nM and 10 nM, respectively. Sunitinib inhibits VEGF-induced proliferation of serum-starved HUVECs with IC50 of 40 nM, and inhibits PDGF-induced proliferation of NIH-3T3 cells overexpressing PDGFRβ or PDGFRα with IC50 of 39 nM and 69 nM, respectively. [2] Sunitinib inhibits phosphorylation of wild-type FLT3, FLT3-ITD, and FLT3-Asp835 with IC50 of 250 nM, 50 nM, and 30 nM, respectively. Sunitinib inhibits the proliferation of MV4;11 and OC1-AML5 cells with IC50 of 8 nM and 14 nM, respectively, and induces apoptosis in a dose-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
3T3 MknwT4lv[XOnIFHzd4F6 NGraOW9KdmirYnn0bY9vKG:oIGDES2YucW6mdXPl[EBDemSXIHnuZ49zeG:{YYTpc44hf2m2aDDJR|UxKG:oIECuNFA4KM7:TR?= NV\YUW1EOTJ4NE[wNVk>
3T3 NWDPTFVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJcohq[mm2aX;uJI9nKFCuYYTlcIV1NWSncnn2[YQh\3Kxd4ToJIZi[3SxcjDpcoR2[2WmIEPUN{Bk\WyuIIDyc4xq\mW{YYTpc44hf2m2aDDJR|UxKG:oIECuNFEh|ryP MX6xNlY1PjBzOR?=
3T3 NIP4W5RHfW6ldHnvckBCe3OjeR?= NEW5NHJKdmirYnn0bY9vKG:oIG\hd4N2dGG{IHXu[I91cGWuaXHsJIdzd3e2aDDmZYN1d3JicnXj[ZB1d3Jid3n0bEBKSzVyIH;mJFAvODVizszN NWXq[nNNOTJ4NE[wNVk>
3T3 MVTLbY5ie2ViQYPzZZk> Ml3TNlAhdWmw NEi1T|FFVVOR Mn\GR4VtdHWuYYKgbY5pcWKrdHnvckBw\iCYRVfGJIlv\HWlZXSgbJVu[W5iS1TSJJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMkKg{txO MnrKNVYyPjJyMEi=
NIH3T3 NEjDU|ZMcW6jc3WgRZN{[Xl? Mn;oNlAhdWmw M1;YOWROW09? MYLpcohq[mm2IHj1cYFvKEuGUjDrbY5ie2ViZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAxNjBzODFOwG0> NFLobm0yPjF4MkCwPC=>
A549 MWHGeY5kfGmxbjDBd5NigQ>? NUK4d|JJTE2VTx?= Ml72TY5pcWKrdHnvckBw\iClLV3leEBl\XCnbnTlcpQhUEeILXnu[JVk\WRiaIXtZY4hSTV2OTDj[YxtKG2rZ4LheIlwdiC5aYToJGlEPTBib3[gNkDPxE1? MY[xPFQ{PDF2NR?=
DU145 MnHWSpVv[3Srb36gRZN{[Xl? Mmi4SG1UVw>? NFXKfWpKdmirYnn0bY9vKG:oIHOtUYV1KGSncHXu[IVvfCCKR1[tbY5lfWOnZDDoeY1idiCGVUG0OUBk\WyuIIPjZZR1\XKrbnege4l1cCCLQ{WwJI9nKDFyIN88US=> Mlr2NVg1OzRzNEW=
KB3-1 NVH2No06S3m2b4TvfIlkKEG|c3H5 M{LRU|czKGh? MmD6SG1UVw>? NHfZb3VEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRNWeyLX7l[4F1cX[nIFvCMVMuOSClZXzsd{B4cXSqIFnDOVAhd2ZiMj6zJO69VQ>? M4\qelE6Ozl5M{Ky
KBV1 NVLmNJRvS3m2b4TvfIlkKEG|c3H5 MYW3NkBp NE\qRVBFVVOR NI\LWIlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRNWeueXPvdJJwfGWrbj3lfJBz\XO|aX7nJGtDXjFiY3XscJMhf2m2aDDJR|UxKG:oIESuNUDPxE1? NFXKW5cyQTN7N{OyNi=>
A375 MVjDfZRwfG:6aXOgRZN{[Xl? M1vpWFczKGh? M1XWTmROW09? MlHKTWM2OD13LkSg{txO NIKzN5MyQTZ3NESwPC=>
RS4-11 MmDjSpVv[3Srb36gRZN{[Xl? MWKyJIg> MYHJcohq[mm2aX;uJI9nKE[OVEOgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFk6KM7:TR?= MXKxPVY2PDRyOB?=
RS4-11 MX;GeY5kfGmxbjDBd5NigQ>? NVTYe3VQOiCq M4rudGlvcGmkaYTpc44hd2ZiRlzUN{BKXERibYX0ZY51KGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODN2IN88US=> NV;zbFRWOTl4NUS0NFg>
Sf9 MoP6T4lv[XOnIFHzd4F6 NUmw[45GOzBibXnu M2T1OGlvcGmkaYTpc44hd2ZiR2PUMZRi\2enZDDWSWdHWiCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFAvOTh3IN88US=> M1;J[|E6QDV2MEWx
Ba/F3 MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPWeZJyPzJiaB?= MXjJR|UxRTFwMjFOwG0> NFLQUY0zODFzN{CwOC=>
BaPTC2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\t[nE4OiCq NXn1dVNrUUN3ME2wMlIzKM7:TR?= MVKyNFEyPzByNB?=
Sf9 MXnGeY5kfGmxbjDBd5NigQ>? NF72TVkyKGh? Moj0SG1UVw>? MmLoTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKaYOteIFo\2WmIGLFWEBmgHC{ZYPz[YQhf2m2aDDJR|UxKG:oIEGuN{DPxE1? MX:yNFEyPzByNB?=
H4 NVfzXmw1S3m2b4TvfIlkKEG|c3H5 M4DzZVExKM7:TR?= MVHUc5hq[2m2eTDpckBpfW2jbjDIOEBk\Wyucx?= M3:xfVIxOzVyOEC2
SF-539 MX;LbY5ie2ViQYPzZZk> M2nVTFM{OyEQvF2= NUfrSow6PjBibXnu MYjEUXNQ MXHJcohq[mm2aX;uJI9nKFCGR1\SZoV1[SCyaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIEGyMlIh|ryP NIf1fJQzODRyM{ewNC=>
U251 NVG5R3dkU2mwYYPlJGF{e2G7 NWS5PXNuOzN|IN88US=> NXvMWJJNPjBibXnu MmTvSG1UVw>? NUXOOopuUW6qaXLpeIlwdiCxZjDWSWdHWjJicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCxPE46KM7:TR?= NEf1b2IzODRyM{ewNC=>
A431 NIrzTWRMcW6jc3WgRZN{[Xl? Mlj2TY5pcWKrdHnvckBw\iCSRFfGVoJmfGFiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAyOi5{IN88US=> NE[wfI0zODV3OEC3Ni=>
A431 NXzTfmdGU2mwYYPlJGF{e2G7 MljWTY5pcWKrdHnvckBw\iCYRVfGVlIh\XiycnXzd4VlKHerdHigTWM2OCCxZjCxPE46KM7:TR?= NUjnbHJYOjB3NUiwO|I>
HepG2 NWHCRox6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWO3NkBp Mme4TWM2OD1|LkixJO69VQ>? MnXGNlA2PzB3Mk[=
Kasumi-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLQcYx3PzJiaB?= MnrvTWM2OD1yLkCxOkDPxE1? NXnU[oNMOjB3N{C1NlY>
RS4-11 M{Dk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\JS3UxPzJiaB?= NFHMZ|RKSzVyPUGg{txO M1zObVIxPTdyNUK2
THP1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHycJlpPzJiaB?= Mln6TWM2OD1yLkWg{txO MVyyNFU4ODV{Nh?=
Kasumi-1 NX7qbpdrTnWwY4Tpc44hSXO|YYm= NXv0TFF{UW6qaXLpeIlwdiCxZjDjMWtqfCCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjBzNTFOwG0> MkiwNlA5OzNyM{m=
A549 NEnhNmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LBbVE3KGh? M2\pSGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIO= MlTQNlE1PTB2NkO=
HL60 NETnSYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXL1WYpxOTZiaB?= NIDtO41CdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzz MnT5NlE1PTB2NkO=
HUVEC MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLWO3kyPiCq MkTiTY5pcWKrdHnvckBw\iCYRVfGMYlv\HWlZXSgZ4VtdCCycn;sbYZmemG2aX;uJJdqfGhiSVO1NEBw\iB{Lke1JO69VQ>? MnTkNlE1PTB2NkO=
HUVEC MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrJNlc4OTZiaB?= MYrJcohq[mm2aX;uJI9nKGKIR1[tbY5lfWOnZDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDRwMESg{txO Mn3vNlE1PTB2NkO=
IM9 Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7ieJBjOTZiaB?= NWnYNJlzSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gTW06KGOnbHzz MorwNlE1PTB2NkO=
K562 NHW1fYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXKxOkBp NG\6TWNCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzz NWrxTFFxOjF2NUC0OlM>
MDA-MB-231 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUmxOkBp M371O2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHN? M4DCZlIyPDVyNE[z
H460 NV\6fG1GS3m2b4TvfIlkKEG|c3H5 M2\jV|czKGh? MmTITWM2OD1{Lkeg{txO MofoNlE3OjF6OEC=
SMMC7721 M1foXGN6fG:2b4jpZ{BCe3OjeR?= MmXDO|IhcA>? MXPJR|UxRTZwNEeg{txO NWrQXmNPOjF4MkG4PFA>
WI38 NGPlcHlEgXSxdH;4bYMhSXO|YYm= MUS3NkBp NHG5bndKSzVyPUiuOVYh|ryP NHHyfJczOTZ{MUi4NC=>
HEK293 MXPLbY5ie2ViQYPzZZk> MUSxNFAhdk1? NXW0O4NCOSCq MmHy[I9meyCwb4SgbY5pcWKrdDDWSWdHNWmwZIXj[YQh[XW2b4Doc5NxcG:{eXzheIlwdiCxZjD0fZJwe2mwZTCxNVc2KHKnc3nkeYUhd25iVlXHSnIzKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJM> NUPYZVZCOjF6OEWyPFc>
HUVEC NWPyUmxkTnWwY4Tpc44hSXO|YYm= MWCxJO69VQ>? NFX6SXczPCCq NYHzXFRSSW62aXHu[4lw\2WwaXOgZYN1cX[rdImgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iVlXHSk1qdmS3Y3XkJINmdGxibXnndoF1cW:w M2\lRVIyQTZ|M{C1
HUVEC M3riSGZ2dmO2aX;uJGF{e2G7 M12yOlEh|ryP NXnXb4RJOSCq NE\4W41KdmirYnn0bY9vKG:oIFXST{BxcG:|cHjvdplt[XSrb36gZZQhXGi{MkCyM3R6ejJyNDDpckBXTUeILYP0bY12dGG2ZXSgTHVXTUN? MUOyNVk3OzNyNR?=
HUVEC M{W1ZWZ2dmO2aX;uJGF{e2G7 MkHDNUDPxE1? MkjhNUBp NX[wdmV7UW6qaXLpeIlwdiCxZjDlUm9UKHCqb4PwbI9zgWyjdHnvckBifCCVZYKtNVE4OiCrbjDWSWdHNXO2aX31cIF1\WRiSGXWSWM> NEfvfZEzOTl4M{OwOS=>
HUVEC M1jCNWtqdmG|ZTDBd5NigQ>? M4L5RlEh|ryP Mn:4NUBp NVW5fYpbUW6qaXLpeIlwdiCxZjDWSWdHWjJicHjvd5Bpd3K7bHH0bY9vKGG2IIT5dk0yOTd3IHnuJHZGT0Zvc4TpcZVt[XSnZDDIWXZGSw>? Mmq4NlE6PjN|MEW=
HUVEC MmfISpVv[3Srb36gRZN{[Xl? MWqxJO69VQ>? M{XEdVEhcA>? NWfkU|hs\G:nczDuc5QhcW6qaXLpeEBCU1RicHjvd5Bpd3K7bHH0bY9vKGG2IGPldk01PzNiaX6gWmVITi2|dHnteYxifGWmIFjVWmVE M2P6T|IyQTZ|M{C1
HL60 MlflR5l1d3SxeHnjJGF{e2G7 MXq1NEDPxE1? NF[xR|M1QCCq MlXzSG1UVw>? NGXjfXRKSzVyPUG1MlUh|ryP NWG0W|BQOjJyMUmxPFg>
K562 NUnjVYJNS3m2b4TvfIlkKEG|c3H5 NW[3RYlvPTBizszN M3nTTlQ5KGh? NUW2Nlc{TE2VTx?= M1Hmd2lEPTB;MkGuPUDPxE1? M33ubVIzODF7MUi4
PC3 MmrLR5l1d3SxeHnjJGF{e2G7 MXq1NEDPxE1? M2\1SlQ5KGh? MXfEUXNQ M130PGlEPTB;MkWuNUDPxE1? NV;ORpNIOjJyMUmxPFg>
SF-539 M4PWd2tqdmG|ZTDBd5NigQ>? MYCzN|Mh|ryP MkTaOlAhdWmw M1OxZ2lvcGmkaYTpc44hd2ZiUFTHSnJj\XSjIIT5do9{cW6nIHvpcoF{\SCjY4Tpeol1gSCrbjDQSGdHNUKELYP0bY12dGG2ZXSgbJVu[W5iU1[tOVM6KGOnbHzzJJdqfGhiSVO1NEBw\iBzMj6yJO69VQ>? M3rqNVIzOjB2N{Sx
HAEC MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\MU3MyODBizszN Ml3XO|IhcA>? MoHZRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQVXDJINmdGy|IHX4dJJme3OrbnegWmVITlJid3n0bEBKSzVyIH;mJFAvOSEQvF2= NWe0dYpQOjJ2NES2O|k>
HT-29 M4DBW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3ue40yODBizszN NXOzb5FNPzJiaB?= NUC4c2VGSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{BmgHC{ZYPzbY5oKF[HR1\SJJdqfGhiSVO1NEBw\iByLkOzJO69VQ>? NFTOb4YzOjR2NE[3PS=>
MV4-11 NETLWnFEgXSxdH;4bYMhSXO|YYm= M1\JclczKGh? NFK4[XFKSzVyPUCuNFA{KM7:TR?= NF\KOWMzOjR3MkWxPC=>
HepG2 NG\kO4dEgXSxdH;4bYMhSXO|YYm= MYK0PEBp MXfJR|UxRTF|LkK0JO69VQ>? NVjMUmdwOjJ2OEO2NFg>
PC9 NFfy[lBEgXSxdH;4bYMhSXO|YYm= NGTPdIE1QCCq M4DRVGlEPTB;MUCuPVch|ryP M1O1fVIzPDh|NkC4
CAKI-1 NWjFUGkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fObFExOCEQvF2= NFTFPVI1QCCq MnroSG1UVw>? M3HzS2dKPTB;MD62N{DPxE1? NEPWTHczOjV4ME[yOy=>
EKVX M{L1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLGNVAxKM7:TR?= NXTrXJhQPDhiaB?= NGm2VHFFVVOR Ml7uS2k2OD15Lkmg{txO MkH3NlI2PjB4Mke=
MCF7 MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DITFExOCEQvF2= MVK0PEBp NG\PUphFVVOR M{TjXWdKPTF;MjFOwG0> MlL0NlI2PjB4Mke=
MDA-MB-435 NHjOWIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XQNlExOCEQvF2= NX7zVoJ1PDhiaB?= MoXlSG1UVw>? Mn3kS2k2Oj1{IN88US=> NV3yblRKOjJ3NkC2Nlc>
OVCAR3 MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDieVEyODBizszN MojlOFghcA>? M4LDOmROW09? MWHHTVU{RTNwMjFOwG0> MknYNlI2PjB4Mke=
SNB19 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnv0NVAxKM7:TR?= NV7CR3lZPDhiaB?= M{jFfGROW09? M{DzZWdKPTR;MUCg{txO Mm\MNlI2PjB4Mke=
SW620 NX3z[GZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYKxNFAh|ryP NWfXXYFJPDhiaB?= Mnz3SG1UVw>? MVzHTVU2RTFwMzFOwG0> MlTWNlI2PjB4Mke=
TK10 NFvUfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjXOWsyODBizszN MnrVOFghcA>? NWO0fph{TE2VTx?= M4G0fGdKPTZ;Nj6zJO69VQ>? NIP3XXkzOjV4ME[yOy=>
UACC257 NF7RPHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVWxNFAh|ryP M2\ZSlQ5KGh? MkfkSG1UVw>? NIWwcVBIUTV5PUSg{txO M4LhXFIzPTZyNkK3
HAEC NVrocm1CS3m2b4TvfIlkKEG|c3H5 NWX4c|BKOTByIN88US=> NEf3TVY4OiCq NVvPTGxUTE2VTx?= MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBXTUeIUjDlfJBz\XO|aX7nJGhCTUNid3n0bEBKSzVyIH;mJFAvOSEQvF2= Ml7FNlMyOzF3NEG=
HT-29 MXPDfZRwfG:6aXOgRZN{[Xl? MVKxNFAh|ryP M1PORVczKGh? NXnveIRiTE2VTx?= MkTJR5l1d3SxeHnjbZR6KGGpYXnud5QhXkWJRmKg[ZhxemW|c3nu[{BpfW2jbjDIWE0zQSClZXzsd{B4cXSqIFnDOVAhd2ZiMD6zN{DPxE1? NFTvdGozOzF|MUW0NS=>
HCT116 MVHGeY5kfGmxbjDBd5NigQ>? MXyyOEBp NID0U4tFVVOR NU\XR40xSW62aX3p[5JifG:{eTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwhdWmpcnH0bY9v NVnRSXZSOjNzNUOyNFA>
HUVEC M13zdGZ2dmO2aX;uJGF{e2G7 NV36fWU3OiEQvF2= NUixR2lSOThiaB?= M4PSVWROW09? NYP3eZJySW62aXHu[4lw\2WwaXOgZYN1cX[rdImgbY4hUFWYRVPzJJVv\GW{IHj5dI95cWNiY3;u[Il1cW:wIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidIXi[UBnd3KvYYTpc44> MY[yN|E2OzJyMB?=
ACHN NWfKU2g4S3m2b4TvfIlkKEG|c3H5 M16wNFYh\A>? M{S4V2lEPTB;Mj61JO69VQ>? NUPCPVI2OjN|NkCxNFQ>
A498 NYrvdWtUS3m2b4TvfIlkKEG|c3H5 MVSxNFAh|ryP MYC3NkBp MUTEUXNQ MVnJR|UxRTRwMzFOwG0> NXTse4J6OjN2OEm2NlY>
HUVEC M3zzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[zJO69VQ>? MmnaNlQhcA>? MUDEUXNQ NVXOd2JKSW62aXHu[4lw\2WwaXOgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDWSWdHNWmwZIXj[YQhfHWkZTDmc5Ju[XSrb36ge4l1cCCHQ{WwJI9nKDBwNkS1JO69VQ>? NGDUWo8zOzV6M{mxNS=>
HUVEC NHPhPFRMcW6jc3WgRZN{[Xl? MVyyNFAh|ryP NVrNcpA3TE2VTx?= NXjGe3hDUW6qaXLpeIlwdiCxZjDWSWdHWjJicHjvd5Bpd3K7bHH0bY9vKGmwIHfyc5d1cCCoYXP0c5Iue3SrbYXsZZRm\CCKVW\FRy=> MWWyN|U5OzlzMR?=
HUVEC NYfTN|JrU2mwYYPlJGF{e2G7 MUmyNFAh|ryP MXfEUXNQ Mkm5TY5pcWKrdHnvckBw\iCYRVfGVlEheGixc4Doc5J6dGG2aX;uJIlvKGe{b4f0bEBn[WO2b4Ktd5RqdXWuYYTl[EBJXV[HQx?= NG\vdXgzOzV6M{mxNS=>
A549 MVHDfZRwfG:6aXOgRZN{[Xl? MnS5O|IhcA>? MUXEUXNQ MUjJR|UxRTJwNESg{txO M3XqSFI{PjB{NESx
HCT116 Mnz3R5l1d3SxeHnjJGF{e2G7 MXG3NkBp NYfLR495TE2VTx?= Mk\OTWM2OD12LkexJO69VQ>? MnfoNlM3ODJ2NEG=
MCF7 NIn4WFBEgXSxdH;4bYMhSXO|YYm= NIi1[ZY4OiCq NXvXR5dLTE2VTx?= Ml7YTWM2OD14LkK5JO69VQ>? MW[yN|YxOjR2MR?=
BGC M4f1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPnfFk4OiCq M1nCfmROW09? M17RNWlEPTB;ND63PEDPxE1? MXyyN|k6QTB2MB?=
BxPC3 M36wVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHiR5Q4OiCq MUTEUXNQ NIjPV41KSzVyPUOuOlMh|ryP MWiyN|k6QTB2MB?=
HT-29 NYPy[GcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;WV|czKGh? NYr6T4VrTE2VTx?= Mk\NTWM2OD1zLkS3JO69VQ>? MlPiNlM6QTlyNEC=
T24 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTGO|IhcA>? M3PFdmROW09? M3rpRWlEPTB;Mj60OEDPxE1? NWTUcnVuOjN7OUmwOFA>
4T1 NFLuR21EgXSxdH;4bYMhSXO|YYm= NWn4TGhsPzJiaB?= MkPTSG1UVw>? MV;JR|UxRTBwMEG2JO69VQ>? MkfKNlQ5QTB4NUK=
MCF7 NIPxW|VEgXSxdH;4bYMhSXO|YYm= Mom4O|IhcA>? Mn;WSG1UVw>? NYHQZ2ZiUUN3ME2wMlAzPzFizszN NEfaPGYzPDh7ME[1Ni=>
MCF7 MUjDfZRwfG:6aXOgRZN{[Xl? M4XNTFczKGh? M{[4emROW09? MXLJR|UxRTBwMEK5N{DPxE1? MWOyOFg6ODZ3Mh?=
MDA-MB-231 MYrDfZRwfG:6aXOgRZN{[Xl? M1fzb|czKGh? Mm[4SG1UVw>? M2OwPGlEPTB;MD6wNlI{KM7:TR?= NEfjbJIzPDh7ME[1Ni=>
MDA-MB-435 NYCzb5V[S3m2b4TvfIlkKEG|c3H5 M33DdVczKGh? NXjvPXVnTE2VTx?= NGHHe49KSzVyPUCuNFA6PyEQvF2= M4\YcVI1QDlyNkWy
MDA-MB-468 MUDDfZRwfG:6aXOgRZN{[Xl? MoTBO|IhcA>? NEjGOFdFVVOR MXXJR|UxRTBwMEC2NUDPxE1? NWL1V|hyOjR6OUC2OVI>
A431 M13jfmtqdmG|ZTDBd5NigQ>? NYe5Tod3OTBizszN NWXqUGQ6OSCq M1rYTGROW09? MVvJcohq[mm2aX;uJI9nKEWJRmKge4l1cCCLQ{WwJI9nKDBwMUeyNUDPxE1? M2DnVlI1QDlyNkWy
SH-SY5Y MVPLbY5ie2ViQYPzZZk> MXyxNEDPxE1? MnTFNUBp NEfic2NFVVOR M{T1RmlvcGmkaYTpc44hd2ZiUFTHSnJj\XSjIIfpeIghUUN3MDDv[kAxNjB6M{Gg{txO MUKyOFg6ODZ3Mh?=
U251 M1TsTGtqdmG|ZTDBd5NigQ>? MknpNVAh|ryP MWKxJIg> NVPZVoVLTE2VTx?= Ml3nTY5pcWKrdHnvckBw\iCYRVfGVlIhf2m2aDDJR|UxKG:oIECuNFE5QSEQvF2= M4DoRlI1QDlyNkWy
Bel7402 M2rCe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGK1RXo4OiCq NHXwWYVFVVOR NX\SUXNmUUN3ME2yMlY4KM7:TR?= MUKyOFkxPDl4MR?=
HK2 NImxVpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPqO|IhcA>? M1XUNGROW09? NEXNO4tKSzVyPUWuPFUh|ryP NXPmOXdlOjR7MES5OlE>
LO2 M1HYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVy3NkBp M3TzVGROW09? Mlm4TWM2OD1zOT65N{DPxE1? MWiyOFkxPDl4MR?=
MV4-11 NGjkXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHydVJmPDhiaB?= MV3EUXNQ NHzTUGRKSzVyPUCuNFA{KM7:TR?= MlTuNlQ6ODR7NkG=
NCI-H3122 M4W4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYH3RVJnPzJiaB?= NX7lbFRqTE2VTx?= M3XoUWlEPTB;MD64N{DPxE1? NYXCVXdoOjR7MES5OlE>
NCI-H460 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYO3NkBp MUHEUXNQ MmnLTWM2OD12LkOxJO69VQ>? NIDyc|YzPDlyNEm2NS=>
NCI-H526 NFLaRppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzMO|IhcA>? MmK5SG1UVw>? M2HmNWlEPTB;MT6wNUDPxE1? M4XaWVI1QTB2OU[x
TT NHXZTZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Pk[|czKGh? M1LaeGROW09? NHflOYZKSzVyPUCuNFQh|ryP MVKyOFkxPDl4MR?=
EoL-1-cell M{fmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jFT2lEPTB;MT62OEBxVQ>? NX7YeGZYW0GQR1XS
MV-4-11 NUOyXWRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzQTWM2OD1{N{KgdG0> M{XM[3NCVkeHUh?=
NOS-1 M1rFZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLSNFFKSzVyPUG1MlMhdk1? MojpV2FPT0WU
CGTH-W-1 MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHjOpRKSzVyPUOwMlk1KG6P MYDTRW5ITVJ?
MONO-MAC-6 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4e0dGlEPTB;M{OuPEBvVQ>? NIPZSW5USU6JRWK=
ALL-PO NXz2cZFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nhc2lEPTB;N{muPFkhdk1? NUL1cZdzW0GQR1XS
NKM-1 NETnbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTl6LkWyJI5O NF;wNnRUSU6JRWK=
KM12 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTN3MD6xOEBvVQ>? MXvTRW5ITVJ?
TE-15 MonGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTVyNz62NUBvVQ>? M3HsO3NCVkeHUh?=
697 M{XCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\xXWlEPTB;NkG0MlI2KG6P MXPTRW5ITVJ?
MOLT-16 M4jzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7XXGVKSzVyPU[zNU4{OiCwTR?= M3HNenNCVkeHUh?=
GB-1 NVHqVWdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nCTmlEPTB;N{GwMlI{KG6P MWHTRW5ITVJ?
TE-12 NF21XHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH6V4JMUUN3ME24NFQvPTVibl2= MnLkV2FPT0WU
ES6 NXW2R|FLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTl6MT6wOkBvVQ>? M3O3XnNCVkeHUh?=
LC-2-ad NVixZ41UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1i0NWlEPTB;MT6xNVQxPyEQvF2= Ml7YV2FPT0WU
BL-70 NX;ifI1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTFwMUG4OFYh|ryP NV;uRW9jW0GQR1XS
ETK-1 M4rwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlT1TWM2OD1zLkK4OVgh|ryP NE\IeGVUSU6JRWK=
A4-Fuk MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTFwM{SxOFEh|ryP NEXKdI9USU6JRWK=
OCI-AML2 MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmiwTWM2OD1zLkO2PFUyKM7:TR?= MYPTRW5ITVJ?
SIG-M5 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDXbW1KSzVyPUGuN|cxODlizszN NXmycJpjW0GQR1XS
NCI-SNU-16 MlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HE[WlEPTB;MT60OlQ5PiEQvF2= M1fzdHNCVkeHUh?=
PSN1 NWfUZ4dkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\aclZKSzVyPUGuOVA3PzZizszN MX;TRW5ITVJ?
SR Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFe5dG5KSzVyPUGuOVQ2PzJizszN MX3TRW5ITVJ?
A3-KAW M2TPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fH[2lEPTB;MT62NlU1PiEQvF2= NGXqdpFUSU6JRWK=
KS-1 M3q0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M32zOWlEPTB;MT62PVI1PyEQvF2= MWPTRW5ITVJ?
CTV-1 NIrzU5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL1TWM2OD1zLkeyO|UyKM7:TR?= MWjTRW5ITVJ?
LB1047-RCC NWXvOXJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVr3U|BQUUN3ME2xMlgyPjJ2IN88US=> MoDTV2FPT0WU
EMG-01 NWm2PYJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjYV5F1UUN3ME2xMlg{PTZ|IN88US=> NYPMSGpnW0GQR1XS
TE-11 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFwOEO5PFUh|ryP M4Ll[nNCVkeHUh?=
CMK NYnHUZJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4r6NGlEPTB;MT65OVUyPyEQvF2= M3;vTHNCVkeHUh?=
NB1 NX71UoMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFGxR|dKSzVyPUGuPVYyOTdizszN M2e0OXNCVkeHUh?=
HAL-01 M3\PVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTKO5RbUUN3ME2yMlA2QTR4IN88US=> MWHTRW5ITVJ?
DEL MmDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXG0cIx2UUN3ME2yMlA5PDh{IN88US=> MknQV2FPT0WU
RL95-2 M2\Pdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:4[IlKSzVyPUKuNVEyOzdizszN MYfTRW5ITVJ?
KARPAS-299 M2DFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;acnNvUUN3ME2yMlEyOzF|IN88US=> MlSzV2FPT0WU
EW-16 NIHMd2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJwMUO1NFgh|ryP NUL5Tmt3W0GQR1XS
RS4-11 NGnET4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i4ZmlEPTB;Mj6xO|kzPCEQvF2= NU\DcohIW0GQR1XS
BB30-HNC NGToUIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJwMkKzO|Uh|ryP NF7VZ4dUSU6JRWK=
DOHH-2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJwM{O0N|Eh|ryP NXHyRVlSW0GQR1XS
RPMI-8402 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJwM{O2NVgh|ryP M1jKWnNCVkeHUh?=
BV-173 M37wRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkT5TWM2OD1{LkOzOlYh|ryP NXfscmw6W0GQR1XS
TE-10 MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfGXYFKSzVyPUKuN|Q{QDRizszN NF36fYVUSU6JRWK=
TE-8 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTJwM{ewN|gh|ryP MUXTRW5ITVJ?
K052 NWfFRXFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LNU2lEPTB;Mj60NFIxOiEQvF2= NU\LNnc{W0GQR1XS
KARPAS-45 M33wOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJwNEm0OFYh|ryP NXzrSpo{W0GQR1XS
SK-NEP-1 NEfxT3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXYWFl[UUN3ME2yMlYxOjN5IN88US=> NHHw[ZVUSU6JRWK=
KGN MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJwNkCzN|kh|ryP MWPTRW5ITVJ?
ML-2 MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJwNkO1NVIh|ryP MXTTRW5ITVJ?
LAMA-84 NXjvV3FyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTyXoJEUUN3ME2yMlY6PTR3IN88US=> NXvwfFRZW0GQR1XS
LXF-289 Mlm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJwN{K5PFkh|ryP MoTqV2FPT0WU
A101D MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXjRmxKSzVyPUKuO|g{ODRizszN NHzBZ5BUSU6JRWK=
KY821 Ml;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HSc2lEPTB;Mj63PVc2QCEQvF2= NXLTbXl1W0GQR1XS
ES4 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHlWFJKSzVyPUKuPFA3OjhizszN Mn\uV2FPT0WU
SCC-3 NVnmV3NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfCOGtKSzVyPUKuPFI5QTFizszN M3Xyb3NCVkeHUh?=
NALM-6 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTBTWM2OD1{LkmwOFc{KM7:TR?= M4j5OHNCVkeHUh?=
BL-41 NF;TZlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\FVJlKSzVyPUKuPVEzOjJizszN MYXTRW5ITVJ?
OPM-2 NIXYZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jubGlEPTB;Mz6wOVk2PCEQvF2= NFm5TG5USU6JRWK=
SF126 NX6yZYJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTNwME[xPVgh|ryP NYXzPZN7W0GQR1XS
BE-13 MmHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnyNJZTUUN3ME2zMlI{OTFzIN88US=> M2\URXNCVkeHUh?=
SF268 NVjFVmdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjNfoZRUUN3ME2zMlMzQDZ7IN88US=> M33CWXNCVkeHUh?=
MOLT-4 MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2K2O2lEPTB;Mz6zPVg{QCEQvF2= MV\TRW5ITVJ?
PF-382 MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjhTWM2OD1|LkS0OVch|ryP NEX3PXFUSU6JRWK=
HEL NXLSb|BXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTtZZJLUUN3ME2zMlQ5ODB3IN88US=> NEnjdZdUSU6JRWK=
RPMI-6666 NGf6V|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzOTWM2OD1|LkW0NVcyKM7:TR?= MoHxV2FPT0WU
QIMR-WIL Mmf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLMbINUUUN3ME2zMlY{OzlzIN88US=> MoT4V2FPT0WU
ATN-1 NFLOZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPuTWM2OD1|Lk[3NVE1KM7:TR?= MYrTRW5ITVJ?
BB49-HNC NGC5TppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M16zeWlEPTB;Mz63NFUxQCEQvF2= NFi1fYxUSU6JRWK=
HCE-4 NYHGXHBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTNwN{i2OFIh|ryP NFS1WZdUSU6JRWK=
SK-LMS-1 MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTNwOEOzN|gh|ryP MVfTRW5ITVJ?
MS-1 M3;MTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHJTWM2OD1|LkizO|c5KM7:TR?= M2XOTHNCVkeHUh?=
JAR MmrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HjOGlEPTB;Mz65PFg{OiEQvF2= MYrTRW5ITVJ?
KE-37 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLETIRWUUN3ME20MlA3OTV6IN88US=> M{jUU3NCVkeHUh?=
LB996-RCC M1fBeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3r[oJKSzVyPUSuNVIyPjhizszN MUHTRW5ITVJ?
HH M2nKSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjxTWM2OD12LkKwPVE1KM7:TR?= M2Tib3NCVkeHUh?=
HL-60 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfPO5FKSzVyPUSuNlExPjVizszN Mlq0V2FPT0WU
HOP-62 NYLFfnBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTRwM{O1NkDPxE1? NEDsenNUSU6JRWK=
NOMO-1 MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTRwM{O2PVkh|ryP MYrTRW5ITVJ?
DU-4475 Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13PPGlEPTB;ND6zOlczQSEQvF2= MVzTRW5ITVJ?
LC4-1 Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTRwM{iwO{DPxE1? NVj3dXBsW0GQR1XS
MC116 NGDPdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrRZZdXUUN3ME20MlQ{ODhzIN88US=> MYPTRW5ITVJ?
SW982 MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XCNmlEPTB;ND61OVMxPyEQvF2= MnXkV2FPT0WU
SK-N-DZ MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XYS2lEPTB;ND62O|A6QSEQvF2= NVLPSYRNW0GQR1XS
EW-1 NHPoN4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\lTWM2OD12Lk[3PVEyKM7:TR?= M1Sw[HNCVkeHUh?=
SU-DHL-1 MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfuPW5KSzVyPUSuPFAyPzRizszN NYHI[2c3W0GQR1XS
L-363 MoDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1K4WWlEPTB;ND64NFYzOSEQvF2= MWPTRW5ITVJ?
OS-RC-2 MnT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIL6eYNKSzVyPUSuPFc{OSEQvF2= MUnTRW5ITVJ?
HD-MY-Z NGjKTYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPsTWM2OD13LkG3N|AyKM7:TR?= M1S1ZnNCVkeHUh?=
MHH-PREB-1 NV:xNnI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkC3TWM2OD13LkOyN|EzKM7:TR?= NEn4VWRUSU6JRWK=
HC-1 MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[yTVdoUUN3ME21MlQ{OjlzIN88US=> NWDXZod4W0GQR1XS
SK-MM-2 NUHZNnhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3xb|NKSzVyPUWuOFc5OiEQvF2= NHe5XWdUSU6JRWK=
SH-4 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzJOJVKSzVyPUWuOFg{PyEQvF2= NFPvbnVUSU6JRWK=
MHH-CALL-2 NGjO[|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTVwN{[3NVkh|ryP MX7TRW5ITVJ?
KG-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHYTWM2OD14LkCyPFc5KM7:TR?= MYnTRW5ITVJ?
J-RT3-T3-5 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPpTWM2OD14LkC3PVA6KM7:TR?= MkXoV2FPT0WU
MMAC-SF MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFL4d5ZKSzVyPU[uNVA6PDlizszN MkfNV2FPT0WU
IST-SL2 NELhWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjBZnJ5UUN3ME22MlEzPTF7IN88US=> MmniV2FPT0WU
SW954 NUXQNWdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HHd2lEPTB;Nj6yO|UyPyEQvF2= MYnTRW5ITVJ?
HDLM-2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTZwM{KxNFkh|ryP NY[5NVc2W0GQR1XS
ST486 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPjcnNtUUN3ME22MlM1PzFizszN NEPLfJpUSU6JRWK=
DG-75 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrJTWM2OD14LkSzNFY6KM7:TR?= NVHJUVBuW0GQR1XS
EW-3 NV7keJJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTZwNEOyNFch|ryP M1fEfHNCVkeHUh?=
8-MG-BA NWLxbJNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmSxTWM2OD14LkWxOVA4KM7:TR?= MmPXV2FPT0WU
GT3TKB MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\kNY1KSzVyPU[uOlA4PjNizszN M2i0WHNCVkeHUh?=
KU812 NXrQT4NET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDRUIhKSzVyPU[uOlk1OiEQvF2= NGewRZVUSU6JRWK=
CESS NWjueIt3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPnTWM2OD15LkGwOFM5KM7:TR?= MnW4V2FPT0WU
BC-1 NILJOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvqUY9KSzVyPUeuNlQ5OTJizszN NHHxS3VUSU6JRWK=
MZ1-PC NUCwU|dST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TjNmlEPTB;Nz6zNFM5QSEQvF2= NGj6XlVUSU6JRWK=
NCI-H82 NFHicYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHXcYdyUUN3ME23MlM4QDVizszN NFK0XHVUSU6JRWK=
NCI-H1355 NFyxSHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PiUGlEPTB;Nz60OVgxPCEQvF2= M3vFRnNCVkeHUh?=
RPMI-8226 NYP3XG1NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTdwNUC3N|kh|ryP M{\OUnNCVkeHUh?=
ARH-77 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2P1SmlEPTB;Nz61N|U6PyEQvF2= MXrTRW5ITVJ?
MN-60 M1TOemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nKdmlEPTB;Nz61OFA5QCEQvF2= NFT2VWJUSU6JRWK=
IMR-5 MmDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVi0RWV7UUN3ME23NFU1QDd4IN88US=> NYm1ZoJ2W0GQR1XS
KARPAS-422 NG\GdoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTdwNUeyNFYh|ryP NHyxXGNUSU6JRWK=
CA46 MkDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTdwNUiwNVIh|ryP M2niS3NCVkeHUh?=
SJSA-1 NE[x[XNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13jcGlEPTB;Nz62OlA3OSEQvF2= NHnwXXNUSU6JRWK=
no-11 M1jVNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTdwN{e1OVch|ryP MkDNV2FPT0WU
IST-SL1 M2Dnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfuXnlKSzVyPUiuNFI1OTdizszN MYHTRW5ITVJ?
NCI-H209 NGDCcnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVqwUpRDUUN3ME24MlEyPjV{IN88US=> NHPST3JUSU6JRWK=
TALL-1 M4O0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TFTWlEPTB;OD6xPFM5PCEQvF2= NGjpblhUSU6JRWK=
KMOE-2 M1;ISGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTSenpNUUN3ME24MlE6PDJizszN NFjndmNUSU6JRWK=
HCC1599 NYS3XndYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TKdWlEPTB;OD6xPVk5PyEQvF2= MWrTRW5ITVJ?
CI-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XvR2lEPTB;OD6yNFQyOSEQvF2= M3vkTXNCVkeHUh?=
NCI-H1304 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrYUXRKSzVyPUiuNlA3PjFizszN M4i1XnNCVkeHUh?=
Daudi NIfrdYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j0OWlEPTB;OD6yN|U1PiEQvF2= MYHTRW5ITVJ?
CPC-N NVfrN2s2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGi0cmFKSzVyPUiuNlkyQTlizszN M1vCbHNCVkeHUh?=
MC-CAR M1TaUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXWZ|l5UUN3ME24MlM{PThizszN NVH4foUzW0GQR1XS
SW872 NVvjT3JwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjzOVdSUUN3ME24MlM1PzV6IN88US=> NYmxRnE6W0GQR1XS
OVCAR-4 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRThwNUCzOVEh|ryP NXnhb45LW0GQR1XS
OCUB-M MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXuPWdKSzVyPUiuOVY2ODhizszN NETiVplUSU6JRWK=
SK-PN-DW NVzHVYd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1f3bWlEPTB;OD62NFk5PSEQvF2= MYrTRW5ITVJ?
NCCIT M2fhSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRThwN{G3OFUh|ryP MoXQV2FPT0WU
NCI-H1648 M2nmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfGbnRuUUN3ME25MlE{QDN2IN88US=> MVTTRW5ITVJ?
COR-L279 NXGxT4tZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4KyPGlEPTB;OT6zPVA6KM7:TR?= M{T2dnNCVkeHUh?=
LS-123 M2SwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHDTWM2OD17Lk[4NVYyKM7:TR?= MnrJV2FPT0WU
LP-1 M33HSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrWTWM2OD17Lke4NFg{KM7:TR?= Mn3KV2FPT0WU
NB13 MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f5OWlEPTB;OT63PVk6PCEQvF2= MV3TRW5ITVJ?
ONS-76 NGfvSVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjVeXhKSzVyPUmuPFExOTZizszN MWTTRW5ITVJ?
VA-ES-BJ MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rmUWlEPTB;OT65PVk{OyEQvF2= NInjT4JUSU6JRWK=
GR-ST M1rFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTFyLkKyNFch|ryP MWDTRW5ITVJ?
ES1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTFyLkK5PFQh|ryP NGq1dXdUSU6JRWK=
NB14 NVXUeFU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjITWM2OD1zMD65Nlc4KM7:TR?= MUnTRW5ITVJ?
Ramos-2G6-4C10 NITKbldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFzLkK2OUDPxE1? NYXJOGcxW0GQR1XS
RXF393 MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTFzLkS4N|Qh|ryP NF\PSHhUSU6JRWK=
NCI-H2107 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLDWFZRUUN3ME2xNU42QTh2IN88US=> NF[1[HpUSU6JRWK=
K562 NYDPcolVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTFzLki3NFIh|ryP NEGyNJlUSU6JRWK=
LOUCY M1z5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjhOIZ2UUN3ME2xNU46QDd3IN88US=> NGG1bVRUSU6JRWK=
TGBC1TKB MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDCTWM2OD1zMj6wNFIh|ryP NGqwOm1USU6JRWK=
COLO-320-HSR M3HE[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTFeIZ2UUN3ME2xNk4yPTZ3IN88US=> MV3TRW5ITVJ?
K5 MmHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHPeJNKSzVyPUGyMlI6QDVizszN NXfyblhwW0GQR1XS
BC-3 NEHzWGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LWWmlEPTB;MUKuOFY2OSEQvF2= M4Dw[3NCVkeHUh?=
REH NFfRUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTF{Lk[0PVgh|ryP NUHQUYJWW0GQR1XS
NEC8 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPKOHpKSzVyPUGyMlY5QDdizszN M3nnS3NCVkeHUh?=
IST-MEL1 MmPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jyPGlEPTB;MUKuPFY6PCEQvF2= NXiyN25jW0GQR1XS
NCI-H128 M3HnTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHrdopKSzVyPUGzMlA4OjNizszN NUnnTIw{W0GQR1XS
NCI-H1694 Mo\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrsdY5KSzVyPUGzMlEyPDRizszN MYXTRW5ITVJ?
TGW MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYW0RplOUUN3ME2xN{4{Ojd4IN88US=> MlvaV2FPT0WU
NCI-SNU-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTF|LkO0OUDPxE1? MnXuV2FPT0WU
IST-MES1 NFGwVmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXBTWM2OD1zMz62O|I6KM7:TR?= M3zaOXNCVkeHUh?=
CTB-1 MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXnN29KSzVyPUGzMlczQTRizszN M1;aWnNCVkeHUh?=
HUTU-80 M3Tu[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTF|Lke1O|Mh|ryP NEHTU|hUSU6JRWK=
LAN-6 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\kNJE1UUN3ME2xOE4zPDV5IN88US=> M3\DdXNCVkeHUh?=
KP-N-YS NF3IVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTF2LkK4PVQh|ryP MnXBV2FPT0WU
CCRF-CEM NVLhO5Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUP1RWlPUUN3ME2xOE41OTZ7IN88US=> M{e2UXNCVkeHUh?=
NCI-H1770 NFnFRVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrCTWM2OD1zND61N|Y6KM7:TR?= MWDTRW5ITVJ?
MZ2-MEL NUDv[m9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDmTWM2OD1zNT6yNlUyKM7:TR?= MmHwV2FPT0WU
COR-L88 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\yTWM2OD1zNj6wNFEzKM7:TR?= NY\uVlZDW0GQR1XS
LOXIMVI MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XXU2lEPTB;MU[uNlU3KM7:TR?= NG\XZmZUSU6JRWK=
KALS-1 M2Xacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPjUIJKSzVyPUG2MlU6OzFizszN M2fHO3NCVkeHUh?=
D-283MED NYC2ZZpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fCSmlEPTB;MU[uPFQ5QSEQvF2= NHTzU2lUSU6JRWK=
NCI-H719 M2rQTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGG3UJFKSzVyPUG2MlkyPjFizszN M4TrZXNCVkeHUh?=
MLMA NHTLfmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{i0emlEPTB;MU[uPVkxPyEQvF2= NHqyc21USU6JRWK=
EVSA-T NWS0[GZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7Ic4p2UUN3ME2xO{4xPDh3IN88US=> NFXaRWVUSU6JRWK=
SK-N-FI MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTF5Lk[5NVMh|ryP MWLTRW5ITVJ?
NTERA-S-cl-D1 M3LNVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInPbY1KSzVyPUG3Mlg2PzJizszN MkLwV2FPT0WU
NCI-H1882 M1jpTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTF5Lkm4N|Qh|ryP M{LpZ3NCVkeHUh?=
A704 M3Hhfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fIc2lEPTB;MUeuPVkxPCEQvF2= MX;TRW5ITVJ?
L-428 NEfFUYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfBU|VKSzVyPUG4MlAyPTFizszN NGG0W5VUSU6JRWK=
HCC1187 NHrld4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nq[mlEPTB;MUiuNFE5PyEQvF2= MV7TRW5ITVJ?
NCI-H1581 NFnoUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\xXW9RUUN3ME2xPE4xQDZ4IN88US=> NGf6[YtUSU6JRWK=
BB65-RCC MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jlUmlEPTB;MUiuOFE3OiEQvF2= NFrwPIxUSU6JRWK=
EM-2 NHjxNI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHmTotVUUN3ME2xPE42Pjd{IN88US=> NYT2VmljW0GQR1XS
Raji NYPPXYlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnr3TWM2OD1zOT65OVY2KM7:TR?= MljuV2FPT0WU
TE-1 NVi4cFIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTlPWc2UUN3ME2yNE41OTB2IN88US=> NIfZbopUSU6JRWK=
SW962 NXznRYdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJyLkSyPVMh|ryP Mke5V2FPT0WU
MHH-NB-11 MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7ZTWM2OD1{MD61OVIyKM7:TR?= NHL0SmRUSU6JRWK=
no-10 NU\rVFRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojxTWM2OD1{MT6wNlY1KM7:TR?= MYnTRW5ITVJ?
GDM-1 NWDWdnVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULEZZU3UUN3ME2yNU46PDF2IN88US=> Mlj0V2FPT0WU
KMS-12-PE MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJ{LkK3OEDPxE1? NFu4SndUSU6JRWK=
NCI-H510A M{HiS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X2c2lEPTB;MkSuNVI4QCEQvF2= NWDvSHN{W0GQR1XS
ES5 NUfFdpo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fBUmlEPTB;MkSuO|M1QSEQvF2= MUjTRW5ITVJ?
JiyoyeP-2003 NHGzNHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTJ4LkK3OFIh|ryP NXTSfpl5W0GQR1XS
NMC-G1 NHjZcIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTvcnFzUUN3ME2yO{4yQDJ{IN88US=> MXjTRW5ITVJ?
NCI-H446 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXzTWM2OD1{Nz60PVQ3KM7:TR?= NEGyfmNUSU6JRWK=
NB7 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTJ5LkmyNlkh|ryP MojZV2FPT0WU
A388 Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJ6LkCwO|Qh|ryP Mnz0V2FPT0WU
JVM-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWCwdJNrUUN3ME2yPE4zQDl6IN88US=> MlnqV2FPT0WU
HT-144 NHO0O4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIK3UI5KSzVyPUK4MlY6KM7:TR?= NWXNZZpbW0GQR1XS
NCI-H747 NXnaeFlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPvNZZ1UUN3ME2yPE46OTl3IN88US=> NILO[GFUSU6JRWK=
NCI-H1650 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjPeJBKUUN3ME2yPU4xOTd4IN88US=> MofsV2FPT0WU
EB-3 NE\HS3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrXOIhQUUN3ME2yPU42OzB7IN88US=> NIrTWIVUSU6JRWK=
KLE MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;TTWM2OD1{OT62NVkh|ryP NGrKZ41USU6JRWK=
TK10 NFTYVJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1T0T2lEPTB;M{CuNVI3KM7:TR?= NHWydI5USU6JRWK=
COLO-668 MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXCVVd1UUN3ME2zNE44QTJizszN MWrTRW5ITVJ?
NCI-H23 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTNzLkGwOlMh|ryP NYXMSWFJW0GQR1XS
GOTO NHToTIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTNzLk[wPFUh|ryP M1XNSXNCVkeHUh?=
MSTO-211H MoPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLpTWM2OD1|MT64Olc5KM7:TR?= M2LPWXNCVkeHUh?=
LB831-BLC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTN{LkO4OFMh|ryP NH\LT5hUSU6JRWK=
SCH MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\CTWM2OD1|Mj64OFg2KM7:TR?= NGPqenpUSU6JRWK=
EHEB MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTN2LkGxPVMh|ryP NWfBUFJjW0GQR1XS
U-266 M{nlemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPuTWM2OD1|ND6yO|gyKM7:TR?= NVTNeJY3W0GQR1XS
EW-11 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3H2S2lEPTB;M{SuOFczPSEQvF2= MV7TRW5ITVJ?
TE-9 M4TNcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTN5LkC0NFEh|ryP NUC2UZpMW0GQR1XS
ES3 M13TdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTy[HRHUUN3ME2zO{42ODB2IN88US=> M1X6OHNCVkeHUh?=
NCI-H2141 Ml;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4W4[2lEPTB;M{iuNFg1OyEQvF2= M{S5dXNCVkeHUh?=
MPP-89 NHTPcXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfWbFFuUUN3ME20Nk4xPTh4IN88US=> MYHTRW5ITVJ?
SK-MEL-2 M3G1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTR{Lk[0NFUh|ryP MWrTRW5ITVJ?
LC-1F MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1G1eWlEPTB;NEOuN|Y5OiEQvF2= M3\scnNCVkeHUh?=
NH-12 NH\VN49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHkZ3pWUUN3ME20N{46OzV7IN88US=> NWi5V2pOW0GQR1XS
RKO M2T0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13hT2lEPTB;NESuNVI2OiEQvF2= NFr1RpVUSU6JRWK=
KM-H2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzITWM2OD12ND65OVc4KM7:TR?= NV;1V|gzW0GQR1XS
SK-UT-1 NI[0fZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jnbmlEPTB;NEmuPFgzPSEQvF2= MoToV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Consistent with the substantial and selective inhibition of VEGFR2 or PDGFR phosphorylation and signaling in vivo, Sunitinib (20-80 mg/kg/day) exhibits broad and potent dose-dependent anti-tumor activity against a variety of tumor xenograft models including HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435. Sunitinib dosing at 80 mg/kg/day for 21 days leads to complete tumor regression in six of eight mice, without tumor re-growing during a 110-day observation period after the end of treatment. Second round of treatment with Sunitinib remains efficacious against tumors that are not fully regressed during the first round of treatment. Sunitinib treatment results in significant decrease in tumor MVD, with ~40% reduction in SF763T glioma tumors. SU11248 treatment results in a complete inhibition of additional tumor growth of luciferase-expressing PC-3M xenografts, despite no reduction in tumor size. [2] Sunitinib treatment (20 mg/kg/day) dramatically suppresses the growth subcutaneous MV4;11 (FLT3-ITD) xenografts and prolongs survival in the FLT3-ITD bone marrow engraftment model. [3]

Protocol

Kinase Assay:[1]
+ Expand

Biochemical Tyrosine Kinase Assays:

IC50 values for Sunitinib against VEGFR2 (Flk-1) and PDGFRβ are determined using glutathione S-transferasefusion proteins containing the complete cytoplasmic domain of the RTK. Biochemical tyrosine kinase assays to quantitate the trans-phosphorylation activity of VEGFR2 (Flk-1) and PDGFRβ are performed in 96-well microtiter plates precoated (20 μg/well in PBS; incubated overnight at 4 °C) with the peptide substrate poly-Glu,Tyr (4:1). Excess protein binding sites are blocked with the addition of 1-5% (w/v) BSA in PBS. Purified GST-fusion proteins are produced in baculovirus-infected insect cells. GST-VEGFR2 and GST-PDGFRβ are then added to the microtiter wells in 2 × concentration kinase dilution buffer consisting of 100 mM HEPES, 50 mM NaCl, 40 μM NaVO4, and 0.02% (w/v) BSA. The final enzyme concentration for GST-VEGFR2 or GST-PDGFRβ is 50 ng/mL. Twenty-five μL of diluted Sunitinib are subsequently added to each reaction well to produce a range of inhibitor concentrations appropriate for each enzyme. The kinase reaction is initiated by the addition of different concentrations of ATP in a solution of MnCl2 so that the final ATP concentrations spanned the Km for the enzyme, and the final concentration of MnCl2 is 10 mM. The plates are incubated for 5-15 minutes at room temperature before stopping the reaction with the addition of EDTA. The plates are then washed three times with TBST. Rabbit polyclonal antiphosphotyrosine antisera are added to the wells at a 1:10,000 dilution in TBST containing 0.5% (w/v) BSA, 0.025% (w/v) nonfat dry milk, and 100 μM NaVO4 and incubated for 1 hour at 37 °C. The plates are then washed three times with TBST, followed by the addition of goat antirabbit antisera conjugated with horseradish peroxidase (1:10,000 dilution in TBST). The plates are incubated for 1 hour at 37 °C and then washed three times with TBST. The amount of phosphotyrosine in each well is quantitated after the addition of 2,2′-azino-di-[3-ethylbenzthiazoline sulfonate] as substrate.
Cell Research:[3]
+ Expand
  • Cell lines: RS4;11, MV4;11, and OC1-AML5
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24 and 48 hours
  • Method: Cells are starved overnight in medium containing 0.1% FBS prior to addition of Sunitinib and FL (50 ng/mL; FLT3-WT cells only). Proliferation is measured after 48 hours of culture using the Alamar Blue assay or trypan blue cell viability assays. Apoptosis is measured 24 hours after Sunitinib addition by Western blotting to detect cleavage of poly (ADP-ribose) polymerase (PARP) or levels of caspase-3.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Female nu/nu mice implanted s.c. with HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435, and male nu/nu mice bearing luciferase-expressing PC-3M tumors
  • Formulation: Formulated as a carboxymethyl cellulose suspension or as a citrate buffered (pH 3.5) solution
  • Dosages: ~80 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 15 mg/mL (28.16 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 4% DMSO+30% PEG 300+ddH2O 2mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 532.56
Formula

C22H27FN4O2.C4H6O5

CAS No. 341031-54-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02761057 Recruiting Recurrent Renal Cell Carcinoma|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma National Cancer Institute (NCI) April 2016 Phase 2
NCT02779283 Recruiting Untreated Adult Acute Myeloid Leukemia OHSU Knight Cancer Institute|National Cancer Institute (NCI) December 2015 Phase 1
NCT02626754 Enrolling by invitation Renal Cell Carcinoma vghtpe user|Taipei Veterans General Hospital, Taiwan August 2015 Phase 2
NCT02465060 Recruiting Advanced Malignant Neoplasm|Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Solid Neoplasm|Refractory Malignant Neoplasm|Refractory Plasma Cell Myeloma National Cancer Institute (NCI) August 2015 Phase 2
NCT01835158 Active, not recruiting Clear Cell Renal Cell Carcinoma|Metastatic Renal Cell Cancer|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer National Cancer Institute (NCI) July 2013 Phase 2
NCT01740154 Terminated Fatigue|Recurrent Renal Cell Cancer|Stage IV Renal Cell Cancer Case Comprehensive Cancer Center|National Cancer Institute (NCI) September 2012 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PDGFR Signaling Pathway Map

PDGFR Inhibitors with Unique Features

Related PDGFR Products

Tags: buy Sunitinib Malate | Sunitinib Malate supplier | purchase Sunitinib Malate | Sunitinib Malate cost | Sunitinib Malate manufacturer | order Sunitinib Malate | Sunitinib Malate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID